Post by STADA Group

📣 What’s next for biosimilar medicines in Europe? On 7–8 May 2026, the spotlight turns to 📍Amsterdam as the Biosimilar Medicines Conference 2026 brings policy, access and resilience into focus. As new EU pharma legislation, the Critical Medicines Act and the Biotech Act reshape the landscape, biosimilars are gaining momentum as a key driver for more sustainable care and broader access to high-quality treatments. STADA’s Dr. Christine Berndt, Chair of the Biosimilar Medicines Group at Medicines for Europe, will join the exchange on how to unlock the full potential of biosimilar medicines across Europe. Register here: https://shorturl.at/u1b94 #CaringForPeoplesHealth